Probiotics: controversial issues | CMAC

Probiotics: controversial issues

Clinical Microbiology and Antimicrobial Chemotherapy. 2022; 24(4):345-360

​ Andreev V.A., Stetsiouk O.U., Andreeva I.V.
10.36488/cmac.2022.4.345-360
probiotic probiotic microorganisms pharmabiotics antibiotics antimicrobial resistance dosing contraindications
Section
Antimicrobials
Type
Review
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2022; 24(4):345-360

Abstract

Recent studies have strongly confirmed the health benefits of a variety of probiotic microorganisms. However, some issues regarding the use of probiotics currently remain unresolved or ambiguous. This article highlights some controversial issues of probiotic use in clinical practice such as regulatory status of probiotics, co-administration of probiotics and antibiotics, potential impact of probiotics on antimicrobial resistance emergence and spread, dosing and duration of probiotic use, contraindications and some other debatable topics.

Andreev V.A.

Smolensk State Medical University, Smolensk, Russia

Olga U. Stetsiouk

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Irina V. Andreeva

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

  • 1. Lee Y.K., Salminen S. The coming of age of probiotics. Trends Food Sci Technol. 1995;6:241-245. DOI: 10.1016/S0924-2244(00)89085-8
  • 2. Probiotics Market by Product Type (Functional Food & Beverages, Dietary Supplements, and Feed), Ingredient (Bacteria and Yeast), End User (Human and Animal), Distribution Channel, and Region – Global Forecast to 2027. Available at: www.marketsandmarkets.com/Market-Reports/probiotic-market-advanced-technologiesand-global-market-69.html. Accessed November, 2022.
  • 3. Ivashkin V.T., Mayev I.V., Abdulganieva D.I., Alekseenko S.A., Gorelov A.V., Zakharova I.N., et al. Practical recommendations of scientific society for the study of human microbiome and the Russian Gastroenterological Association on use of probiotics, prebiotics, synbiotics and functional foods in treatment and prevention of gastroenterological diseases in children and adults. Russian journal of gastroenterology, hepatology, coloproctology. 2021;31(2):65-91. Russian. DOI: 10.22416/13824376-2021-31-2-65-91
  • 4. GOST R 52349-2005 Food products. Functional food products. Terms and definitions (with Amendment No. 1). Date of effect 2006-07- 01. Russian.
  • 5. GOST P 55577-2013. National Standard of the Russian Federation. Specialized and functional food products. Information on distinguishing characters and efficacy. Russian.
  • 6. GOST R 54059-2010. National Standard of the Russian Federation. Functional food products. Functional food ingredients. Classification and general requirements. Russian.
  • 7. TR CU 021/2011 Technical Regulation of the Customs Union “On Food Safety” of 9 December, 2011, No. 880 (as amended on 8 August, 2019). Russian.
  • 8. SanPiN 2.3.2.1290 – 03.2.3.2. (p 2.1) «Food raw materials and food products. Hygienic requirements for the organization of dietary supplements production and turnover. Sanitary and epidemiological rules and regulations”, approved by the Chief Public Health Officer of the Russian Federation on 17.04.2003 № 50. Russian.
  • 9. Federal Law of the Russian Federation of 12 April, 2010, No. 61-FZ «On Regulation of Drugs». Russian.
  • 10. Order of the Ministry of Health of the Russian Federation No. 403n of 11 July, 2017, “On approval of rules for dispensing drugs for medical use, including immunobiological drugs, by pharmaceutical organisations and individual entrepreneurs licensed to conduct pharmaceutical activities” of 12 September, 2017. Russian.
  • 11. General pharmacopoeial article “Probiotics” OFS.1.7.1. 0008.15 of the Ministry of Health of the Russian Federation. Russian.
  • 12. Lee E.S., Song E.J., Nam Y.D., Lee S.Y. Probiotics in human health and disease: from nutribiotics to pharmabiotics. J Microbiol. 2018;56(11):773-782. DOI: 10.1007/s12275-018-8293-y
  • 13. Hill C., Guarner F., Reid G., Gibson G.R., Merenstein D.J., Pot B., et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506-514. DOI: 10.1038/nrgastro.2014.66
  • 14. Shanahan F., Stanton C., Ross P., Hill C. Pharmabiotics, bioactives from mining host-microbe-dietary interactions. Funct Food Rev. 2009;1:20-25.
  • 15. LeBegue C.E., Love B.L., Wyatt M.D. Microbes as drugs: the potential of pharmabiotics. Pharmacotherapy. 2020;40(2):102-106. DOI: 10.1002/phar.2357
  • 16. Hill C. Probiotics and pharmabiotics: alternative medicine or an evidence-based alternative? Bioeng Bugs. 2010;1(2):79-84. DOI: 10.4161/bbug.1.2.10796
  • 17. D’Aimmo M.R., Modesto M., Biavati B. Antibiotic resistance of lactic acid bacteria and Bifidobacterium spp. isolated from dairy and pharmaceutical products. Int J Food Microbiol. 2007;115(1):35-42. DOI: 10.1016/j.ijfoodmicro.2006.10.003
  • 18. Klare I., Konstabel C., Werner G., Huys G., Vankerckhoven V., Kahlmeter G., et al. Antimicrobial susceptibilities of Lactobacillus, Pediococcus and Lactococcus human isolates and cultures intended for probiotic or nutritional use. J Antimicrob Chemother. 2007;59(5):900-912. DOI: 10.1093/jac/dkm035
  • 19. Anisimova E.A., Yarullina D.R. Antibiotic resistance of Lactobacillus strains. Curr Microbiol. 2019;76(12):14071416. DOI: 10.1007/s00284-019-01769-7
  • 20. Comunian R., Daga E., Dupré I., Paba A., Devirgiliis C., Piccioni V., et al. Susceptibility to tetracycline and erythromycin of Lactobacillus paracasei strains isolated from traditional Italian fermented foods. Int J Food Microbiol. 2010;138(1-2):151-156. DOI: 10.1016/j.ijfoodmicro.2009.11.018
  • 21. Masco L., Van Hoorde K., De Brandt E., Swings J., Huys G. Antimicrobial susceptibility of Bifidobacterium strains from humans, animals and probiotic products. J Antimicrob Chemother. 2006;58(1):85-94. DOI: 10.1093/jac /jac/dkl197
  • 22. Moubareck C., Gavini F., Vaugien L., Butel M.J., DoucetPopulaire F. Antimicrobial susceptibility of bifidobacteria. J Antimicrob Chemother. 2005;55(1):38-44. DOI: 10.1093/jac/dkh495
  • 23. Xu J., Liu X., Yang B., Li Z. [Antimicrobial susceptibility of probiotics]. Wei Sheng Yan Jiu. 2008;37(3):354-356. PMID: 18646539.
  • 24. Neut C., Mahieux S., Dubreuil L.J. Antibiotic susceptibility of probiotic strains: is it reasonable to combine probiotics with antibiotics? Med Mal Infect. 2017;47(7):477-483. DOI: 10.1016/j.medmal.2017.07.001
  • 25. McFarland L.V. From yaks to yogurt: the history, development, and current use of probiotics. Clin Infect Dis. 2015;60(Suppl. 2):S85-90. DOI: 10.1093/cid/civ054
  • 26. Adams C.A. The probiotic paradox: live and dead cells are biological response modifiers. Nutr Res Rev. 2010;23(1):3746. DOI: 10.1017/S0954422410000090
  • 27. Lebeer S., Vanderleyden J., De Keersmaecker S.C. Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nat Rev Microbiol. 2010;8(3):171-184. DOI: 10.1038/nrmicro2297
  • 28. Corr S.C., Hill C., Gahan C.G. Understanding the mechanisms by which probiotics inhibit gastrointestinal pathogens. Adv Food Nutr Res. 2009;56:1-15. DOI: 10.1016/S1043-4526(08)00601-3
  • 29. D’Souza A.L., Rajkumar C., Cooke J., Bulpitt C.J. Probiotics in prevention of antibiotic associated diarrhoea: metaanalysis. BMJ. 2002;324(7350):1361. DOI: 10.1136/bmj.324.7350.1361
  • 30. Cremonini F., Di Caro S., Nista E.C., Bartolozzi F., Capelli G., Gasbarrini G., et al. Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther. 2002;16(8):1461-1467. DOI: 10.1046/j.1365-2036.2002.01318.x
  • 31. Szajewska H., Ruszczyński M., Radzikowski A. Probiotics in the prevention of antibiotic-associated diarrhea in children: a meta-analysis of randomized controlled trials. J Pediatr. 2006;149(3):367-372. DOI: 10.1016/j.jpeds.2006.04.053
  • 32. Johnston B.C., Goldenberg J.Z., Vandvik P.O., Sun X., Guyatt G.H. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2011;11:CD004827. DOI: 10.1002/14651858.CD004827.pub3
  • 33. Hempel S., Newberry S.J., Maher A.R., Wang Z., Miles J.N., Shanman R., et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012;307(18):19591969. DOI: 10.1001/jama.2012.3507
  • 34. Goldenberg J.Z., Ma S.S., Saxton J.D,. Martzen M.R., Vandvik P.O., Thorlund K., et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2013;5: CD006095. DOI: 10.1002/14651858.CD006095.pub3
  • 35. Goldenberg J.Z., Lytvyn L., Steurich J., Parkin P., Mahant S., Johnston B.C. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2015;12:CD004827. DOI: 10.1002/14651858.CD004827.pub4
  • 36. Szajewska H., Kołodziej M. Systematic review with metaanalysis: Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults. Aliment Pharmacol Ther. 2015;42(10):1149-1157. DOI: 10.1111/apt.13404
  • 37. Jafarnejad S., Shab-Bidar S., Speakman J.R., Parastui K., Daneshi-Maskooni M., Djafarian K. Probiotics reduce the risk of antibiotic-associated diarrhea in adults (1864 years) but not the elderly (> 65 years): a metaanalysis. Nutr Clin Pract. 2016;31(4):502-513. DOI: 10.1177/0884533616639399
  • 38. Goldenberg J.Z., Yap C., Lytvyn L., Lo C.K., Beardsley J., Mertz D., Johnston B.C. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2017;12: CD006095. DOI: 10.1002/14651858.CD006095.pub4
  • 39. Shen N.T., Maw A., Tmanova L.L., Pino A., Ancy K., Crawford C.V., et al. Timely use of probiotics in hospitalized adults prevents Сlostridium difficile infection: a systematic review with meta-regression analysis. Gastroenterology. 2017;152(8):1889-1900. DOI: 10.1053/j.gastro.2017.02.003
  • 40. Blaabjerg S., Artzi D.M., Aabenhus R. Probiotics for the prevention of antibiotic-associated diarrhea in outpatients – a systematic review and meta-analysis. Antibiotics (Basel). 2017;6(4):21. DOI: 10.3390/antibiotics6040021
  • 41. Guo Q., Goldenberg J.Z., Humphrey C., El Dib R., Johnston B.C. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2019;4:CD004827. DOI: 10.1002/14651858.CD004827.pub5
  • 42. Ma Y., Yang J.Y., Peng X., Xiao K.Y., Xu Q., Wang C. Which probiotic has the best effect on preventing Clostridium difficile-associated diarrhea? A systematic review and network meta-analysis. J Dig Dis. 2020;21(2):69-80. DOI: 10.1111/1751-2980.12839
  • 43. Goodman C., Keating G., Georgousopoulou E., Hespe C., Levett K. Probiotics for the prevention of antibiotic-associated diarrhoea: a systematic review and meta-analysis. BMJ Open. 2021;11(8):e043054. DOI: 10.1136/bmjopen-2020-043054
  • 44. Liao W., Chen C., Wen T., Zhao Q. Probiotics for the prevention of antibiotic-associated diarrhea in adults: a meta-analysis of randomized placebo-controlled trials. J Clin Gastroenterol. 2021;55(6):469-480. DOI: 10.1097/MCG.0000000000001464
  • 45. Williams Zhang L., Zeng X., Guo D., Zou Y, Gan H., Huang X. Early use of probiotics might prevent antibioticassociated diarrhea in elderly (> 65 years): a systematic review and meta-analysis. BMC Geriatr. 2022;22(1):562. DOI: 10.1186/s12877-022-03257-3
  • 46. WGO Practice Guideline. Probiotics and prebiotics. World Gastroenterology Organization. 2012. Available at: www.worldgastroenterology.org/guidelines/global-guidelines/probiotics-and-prebiotics. Accessed November 16, 2022.
  • 47. Szajewska H., Canani R.B., Guarino A., Hojsak I., Indrio F., Kolacek S., et al; ESPGHAN Working Group for Probiotics and Prebiotics. Probiotics for the prevention of antibiotic-associated diarrhea in children. J Pediatr Gastroenterol Nutr. 2016;62(3):495-506. DOI: 10.1097/MPG.0000000000001081
  • 48. Guarner F., Sanders M.E., Eliakim R., Fedorak R., Gangl A., Garisch J., et al. World Gastroenterology Organization Global Guidelines. Probiotics and prebiotics. February 2017. Available at: www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebioticsenglish-2017.pdf. Accessed November 16, 2022.
  • 49. Williams N.T. Probiotics. Am J Health Syst Pharm. 2010;67(6):449-458. DOI: 10.2146/ajhp090168
  • 50. Malfertheiner P., Megraud F., O’Morain C.A., Gisbert J.P., Kuipers E.J., Axon A.T., et al. Management of Helicobacter pylori infection – the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30. DOI: 10.1136/gutjnl-2016-312288
  • 51. Wermeille J., Cunningham M., Dederding J.P., Girard L., Baumann R., Zelger G., et al. Failure of Helicobacter pylori eradication: is poor compliance the main cause? Gastroenterol Clin Biol. 2002;26(3):216-219. PMID: 11981460.
  • 52. Sanches B., Coelho L., Moretzsohn L., Vieira G Jr. Failure of Helicobacter pylori treatment after regimes containing clarithromycin: new practical therapeutic options. Helicobacter. 2008;13(6):572-576. DOI: 10.1111/j.1523-5378.2008.00649.x
  • 53. Gong Y., Li Y., Sun Q. Probiotics improve efficacy and tolerability of triple therapy to eradicate Helicobacter pylori: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2015;8(4):6530-6543. PMID: 26131283.
  • 54. Bulgakov S.A. Side effects of antihelicobacter therapy. Almanac of clinical medicine. 2006;14:20-23. Russian.
  • 55. Marteau P., Rambaud J.C. Potential of using lactic acid bacteria for therapy and immunomodulation in man. FEMS Microbiol Rev. 1993;12:207-220. DOI: 10.1111/j.1574-6976.1993.tb00019.x
  • 56. Zakharenko S.M., Andreeva I.V., Stetsyuk O.U. Gastrointestinal adverse drug reactions and antibioticassociated diarrhea during antibiotic therapy in outpatient practice: prevention and treatment. Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2019;21(3):196-206. Russian. DOI: 10.36488/cmac.2019.3.196-206
  • 57. Tong J.L., Ran Z.H., Shen J., Zhang C.X., Xiao S.D. Metaanalysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2007; 25(2):155-168. DOI: 10.1111/j.1365-2036.2006.03179.x
  • 58. Zou J., Dong J., Yu X. Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter. 2009; 14(5):97-107. DOI: 10.1111/j.1523-5378.2009.00716.x
  • 59. Wang Z.H., Gao Q.Y., Fang J.Y. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol. 2013;47(1):25-32. DOI: 10.1097/MCG.0b013e318266f6cf
  • 60. Zheng X., Lyu L., Mei Z. Lactobacillus-containing probiotic supplementation increases Helicobacter pylori eradication rate: evidence from a meta-analysis. Rev Esp Enferm Dig. 2013;105(8):445-453. DOI: 10.4321/s113001082013000800002
  • 61. Li S., Huang X.L., Sui J.Z., Chen S.Y., Xie Y.T., Deng Y., et al. Meta-analysis of randomized controlled trials on the efficacy of probiotics in Helicobacter pylori eradication therapy in children. Eur J Pediatr. 2014;173(2):153-161. DOI: 10.1007/s00431-013-2220-3
  • 62. Lv Z., Wang B., Zhou X., Wang F., Xie Y., Zheng H., et al. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: a meta-analysis. Exp Ther Med. 2015;9(3):707-716. DOI: 10.3892/etm.2015.2174
  • 63. Zhang M.M., Qian W., Qin Y.Y., He J., Zhou Y.H. Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis. World J Gastroenterol. 2015; 21(14):4345-4357. DOI: 10.3748/wjg.v21.i14.4345
  • 64. Lü M., Yu S., Deng J., Efficacy of probiotic supplementation therapy for Helicobacter pylori eradication: a metaanalysis of randomized controlled trials. PLoS One. 2016;11(10):e0163743. DOI: 10.1371/journal.pone.0163743
  • 65. Si X.B., Lan Y., Qiao L. A meta-analysis of randomized controlled trials of bismuth-containing quadruple therapy combined with probiotic supplement for eradication of Helicobacter pylori. Zhonghua Nei Ke Za Zhi. 2017;56(10):752-759. DOI: 10.3760/cma.j.issn.0578-1426.2017.10.009
  • 66. Fang H. R., Zhang G.Q., Cheng J.Y., Li Z.Y. Efficacy of Lactobacillus-supplemented triple therapy for Helicobacter pylori infection in children: a meta-analysis of randomized controlled trials. Eur J Pediatr. 2019;178(1):7-16. DOI: 10.1007/s00431-018-3282-z
  • 67. Shi X., Zhang J., Mo L., Shi J., Qin M., Huang X. Efficacy and safety of probiotics in eradicating Helicobacter pylori: a network meta-analysis. Medicine (Baltimore). 2019;98(15):e15180. DOI: 10.1097/MD.0000000000015180
  • 68. Malfertheiner P., Megraud F., O’Morain C.A., Atherton J., Axon A.T., Bazzoli F., et al.; European Helicobacter Study Group Management of Helicobacter pylori infection – the Maastricht IV. Florence Consensus Report. Gut. 2012;61(5):646-664. DOI: 10.1136/gutjnl-2012-302084
  • 69. WHO global strategy for containment of antimicrobial resistance. World Health Organization. Geneva: World Health Organization; 2001 (WHO/CDS/CSR/DRS/2001.2). Available at: https://apps.who.int/iris/handle/10665/66860.
  • 70. Ouwehand A.C., Forssten S., Hibberd A.A., Lyra A., Stahl B. Probiotic approach to prevent antibiotic resistance. Ann Med. 2016;48(4):246-255. DOI: 10.3109/07853890.2016.1161232
  • 71. Szajewska H., Guarino A., Hojsak I., Indrio F., Kolacek S., Shamir R., et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Use of probiotics for management of acute gastroenteritis: a position paper by the ESPGHAN Working Group for Probiotics and Prebiotics. J Pediatr Gastroenterol Nutr. 2014;58(4):531539. DOI: 10.1097/MPG.0000000000000320
  • 72. Shim Y.H., Lee S.J., Lee J.W. Antimicrobial activity of lactobacillus strains against uropathogens. Pediatr Int. 2016;58(10):1009-1013. DOI: 10.1111/ped.12949
  • 73. Allen-McFarlane R.S. Lactobacillus parafarraginis KU495926 inhibits multi-drug resistant and extended spectrum beta-lactamase producing gram-negative bacteria. Proceedings of ASM Microbe; June 1-5, 2017; New Orleans.
  • 74. Romário Silva D., de Cássia Orlandi Sardi J., de Souza Pitangui N., Magri Roque S., Cristina Barbosa da Silva A., Luiz Rosalen P. Probiotics as an alternative antimicrobial therapy: current reality and future directions. J Functional Foods. 2020;73:104080. DOI: 10.1016/j.jff.2020.104080
  • 75. Zimmermann P., Curtis N. The effect of antibiotics on the composition of the intestinal microbiota – a systematic review. J Infect. 2019;79(6):471-489. DOI: 10.1016/j.jinf.2019.10.008
  • 76. Jernberg C., Löfmark S., Edlund C., Jansson J.K. Longterm ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J. 2007;1(1):56-66. DOI: 10.1038/ismej.2007.3
  • 77. Sjölund M., Tano E., Blaser M.J., Andersson D.I., Engstrand L. Persistence of resistant Staphylococcus epidermidis after single course of clarithromycin. Emerg Infect Dis. 2005;11:1389-1393. DOI: 10.3201/eid1109.050124
  • 78. Jakobsson H., Wreiber K., Fall K., Fjelstad B., Nyrén O., Engstrand L. Macrolide resistance in the normal microbiota after Helicobacter pylori treatment. Scand J Infect Dis. 2007;39(9):757-763. DOI: 10.1080/00365540701299608
  • 79. Löfmark S., Jernberg C., Jansson J.K., Edlund C. Clindamycin-induced enrichment and long-term persistence of resistant Bacteroides spp. and resistance genes. J Antimicrob Chemother. 2006;58(6):1160-1167. DOI: 10.1093/jac/dkl420
  • 80. Dethlefsen L., Huse S., Sogin M.L., Relman D.A. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 2008;6(11):e280. DOI: 10.1371/journal.pbio.0060280
  • 81. Zaura E., Brandt B.W., Teixeira de Mattos M.J., Buijs M.J., Caspers M.P., Rashid M.U., et al. Same exposure but two radically different responses to antibiotics: resilience of the salivary microbiome versus long-term microbial shifts in feces. MBio. 2015;6(6):e01693-15. DOI: 10.1128/mBio.01693-15
  • 82. Palleja A., Mikkelsen K.H., Forslund S.K., Kashani A., Allin K.H., Nielsen T., et al. Recovery of gut microbiota of healthy adults following antibiotic exposure. Nat Microbiol. 2018;3(11):1255-1265. DOI: 10.1038/s41564-0180257-9
  • 83. Elvers K.T., Wilson V.J., Hammond A., Duncan L., Huntley A.L., Hay A.D., et al. Antibiotic-induced changes in the human gut microbiota for the most commonly prescribed antibiotics in primary care in the UK: a systematic review. BMJ Open. 2020;10(9):e035677. DOI: 10.1136/bmjopen-2019-035677
  • 84. Nel Van Zyl K., Matukane S.R., Hamman B.L., Whitelaw A.C., Newton-Foot M. Effect of antibiotics on the human microbiome: a systematic review. Int J Antimicrob Agents. 2022;59(2):106502. DOI: 10.1016/j.ijantimicag.2021.106502
  • 85. Farnworth E.R. The evidence to support health claims for probiotics. J Nutr. 2008;138(6):1250S-1254S. DOI: 10.1093/jn/138.6.1250S
  • 86. Sniffen J.C., McFarland L.V., Evans C.T., Goldstein E.J.C. Choosing an appropriate probiotic product for your patient: an evidence-based practical guide. PLoS One. 2018;13(12):e0209205. DOI: 10.1371/journal.pone.0209205
  • 87. Ouwehand A.C. A review of dose-responses of probiotics in human studies. Benef Microbes. 2017;8(2):143-151. DOI: 10.3920/BM2016.0140
  • 88. Hamilton-Miller J.M.T. Probiotics – panacea or nostrum? Nutrition Bulletin. 1996;21:199-208. DOI: 10.1111/j.1467-3010.1996.tb00853.x
  • 89. Hatakka K., Savilahti E., Pönkä A., Meurman J.H., Poussa T., Näse L., et al. Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial. BMJ. 2001;322(7298):1327. DOI: 10.1136/bmj.322.7298.1327
  • 90. Näse L., Hatakka K., Savilahti E., Saxelin M., Pönkä A., Poussa T., et al. Effect of long-term consumption of a probiotic bacterium, Lactobacillus rhamnosus GG, in milk on dental caries and caries risk in children. Caries Res. 2001;35(6):412-420. DOI: 10.1159/000047484
  • 91. Basu S., Chatterjee M., Ganguly S., Chandra P.K. Effect of Lactobacillus rhamnosus GG in persistent diarrhea in Indian children: a randomized controlled trial. J Clin Gastroenterol. 2007;41(8):756-760. DOI: 10.1097/01.mcg.0000248009.47526.ea
  • 92. Basu S., Paul D.K., Ganguly S., Chatterjee M., Chandra P.K. Efficacy of high-dose Lactobacillus rhamnosus GG in controlling acute watery diarrhea in Indian children: a randomized controlled trial. J Clin Gastroenterol. 2009;43(3):208-213. DOI: 10.1097/MCG.0b013e31815a5780
  • 93. Kligler B., Cohrssen A. Probiotics. Am Fam Physician. 2008;78(9):1073-1078. PMID: 19007054.
  • 94. Stavropoulou E., Bezirtzoglou E. Probiotics in medicine: a long debate. Front Immunol. 2020;11:2192. DOI: 10.3389/fimmu.2020.02192
  • 95. Li B.Z., Threapleton D.E., Wang J.Y., Xu J.M., Yuan J.Q., Zhang C., et al. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ. 2015;351:h4052. DOI: 10.1136/bmj.h4052
  • 96. Zhang Y., Li L., Guo C., Mu D., Feng B., Zuo X., et al. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis. BMC Gastroenterol. 2016;16(1):62. DOI: 10.1186/s12876-016-0470-z
  • 97. Zhao Y., Dong B.R., Hao Q. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev. 2022;8(8):CD006895. DOI: 10.1002/14651858.CD006895.pub4
  • 98. Jiang W., Ni B., Liu Z., Liu X., Xie W., Wu I.X.Y., et al. The role of probiotics in the prevention and treatment of atopic dermatitis in children: an updated systematic review and meta-analysis of randomized controlled trials. Paediatr Drugs. 2020;22(5):535-549. DOI: 10.1007/s40272020-00410-6
  • 99. Dalal R., McGee R.G., Riordan S.M., Webster A.C. Probiotics for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2017;2(2):CD008716. DOI: 10.1002/14651858.CD008716.pub3
  • 100. Liu R.T., Walsh R.F.L., Sheehan A.E. Prebiotics and probiotics for depression and anxiety: a systematic review and meta-analysis of controlled clinical trials. Neurosci Biobehav Rev. 2019;102:13-23. DOI: 10.1016/j.neubiorev.2019.03.023
  • 101. Sanchez P., Letarouilly J.G., Nguyen Y., Sigaux J., Barnetche T., Czernichow S., et al. Efficacy of probiotics in rheumatoid arthritis and spondyloarthritis: a systematic review and meta-analysis of randomized controlled trials. Nutrients. 2022;14(2):354. DOI: 10.3390/nu14020354
  • 102. Tao Y.W., Gu Y.L., Mao X.Q., Zhang L., Pei Y.F. Effects of probiotics on type II diabetes mellitus: a meta-analysis. J Transl Med. 2020;18(1):30. DOI: 10.1186/s12967020-02213-2
  • 103. Timmerman H.M., Koning C.J., Mulder L., Rombouts F.M., Beynen A.C. Monostrain, multistrain and multispecies probiotics – a comparison of functionality and efficacy. Int J Food Microbiol. 2004;96(3):219-233. DOI: 10.1016/j.ijfoodmicro.2004.05.012
  • 104. Kwoji I.D., Aiyegoro O.A., Okpeku M., Adeleke M.A. Multi-strain probiotics: synergy among isolates enhances biological activities. Biology (Basel). 2021;10(4):322. DOI: 10.3390/biology10040322
  • 105. Collado M.C., Jalonen L., Meriluoto J., Salminen S. Protection mechanism of probiotic combination against human pathogens: in vitro adhesion to human intestinal mucus. Asia Pac J Clin Nutr. 2006;15(4):570-575. PMID: 17077078.
  • 106. Andreeva I.V., Stetsiouk O.U. Efficacy and safety of Lactobacillus acidophilus LA-5 and Bifidobacterium lactis BB-12 combination in gastroenterology, pediatrics and allergology. Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2016;18(2):113-124. Russian.
  • 107. Martins F.S., Silva A.A., Vieira A.T., Barbosa F.H., Arantes R.M., Teixeira M.M., et al. Comparative study of Bifidobacterium animalis, Escherichia coli, Lactobacillus casei and Saccharomyces boulardii probiotic properties. Arch Microbiol. 2009;191(8):623-630. DOI: 10.1007/s00203-009-0491-x
  • 108. Tabasco R., García-Cayuela T., Peláez C., Requena T. Lactobacillus acidophilus La-5 increases lactacin B production when it senses live target bacteria. Int J Food Microbiol. 2009;132(2-3):109-116. DOI: 10.1016/j.ijfoodmicro.2009.04.004
  • 109. Kekkonen R. Immunomodulatory effects of probiotic bacteria in healthy adults. Academic Dissertation. Helsinki. 2008. 122 p.
  • 110. Besselink M.G., van Santvoort H.C., Buskens E., Boermeester M.A., van Goor H,. Timmerman H.M., et al. Dutch Acute Pancreatitis Study Group. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371(9613):651-659. DOI: 10.1016/S01406736(08)60207-X
  • 111. Boyle R.J., Robins-Browne R.M., Tang M.L. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr. 2006;83(6):1256-1264; quiz 1446-7. DOI: 10.1093/ajcn/83.6.1256
  • 112. Natural Medicines Comprehensive Database. Lactobacillus monograph. Available at: www.naturaldatabase.com. Accessed November 21, 2022.
  • 113. Stadlbauer V. Immunosuppression and probiotics: are they effective and safe? Benef Microbes. 2015;6(6):823-828. DOI: 10.3920/BM2015.0065
  • 114. Salminen M.K., Tynkkynen S., Rautelin H., Saxelin M., Vaara M., Ruutu P., et al. Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis. 2002;35:1155-1160. DOI: 10.1086/342912
  • 115. Salminen M.K., Rautelin H., Tynkkynen S., Poussa T., Saxelin M., Valtonen V., et al. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clin Infect Dis. 2004;38:62-69. DOI: 10.1086/380455
  • 116. Borriello S.P., Hammes W.P., Holzapfel W., Marteau P., Schrezenmeir J., Vaara M., et al. Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis. 2003;36:775-780. DOI: 10.1086/368080
  • 117. Hempel S., Newberry S., Ruelaz A., Wang Z., Miles J.N., Suttorp M.J., et al. Safety of probiotics used to reduce risk and prevent or treat disease. Evid Rep Technol Assess (Full Rep). 2011;(200):1-645. PMID: 23126627.
  • 118. Esaiassen E., Hjerde E., Cavanagh J.P., Simonsen G.S., Klingenberg C. Bifidobacterium bacteremia: clinical characteristics and a genomic approach to assess pathogenicity. J Clin Microbiol. 2017;55(7):2234-2248. DOI: 10.1128/JCM.00150-17
  • 119. Weber E., Reynaud Q., Suy F., Gagneux-Brunon A., Carricajo A., Guillot A., et al. Bifidobacterium species bacteremia: risk factors in adults and infants. Clin Infect Dis. 2015;61(3):482-484. DOI: 10.1093/cid/civ347
  • 120. Gouriet F., Million M., Henri M., Fournier P.E., Raoult D. Lactobacillus rhamnosus bacteremia: an emerging clinical entity. Eur J Clin Microbiol Infect Dis. 2012;31(9):24692480. DOI: 10.1007/s10096-012-1599-5
  • 121. Munoz P., Bouza E., Cuenca-Estrella M., Eiros J.M., Pérez M.J., Sánchez-Somolinos M., et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis. 2005;40:1625-1634. DOI: 10.1086/429916
  • 122. Lu D., Yan J., Liu F., Ding P., Chen B., Lu Y., et al. Probiotics in preventing and treating chemotherapy-induced diarrhea: a meta-analysis. Asia Pac J Clin Nutr. 2019;28(4):701710. DOI: 10.6133/apjcn.201912_28(4).0005
  • 123. Hassan H., Rompola M., Glaser A.W., Kinsey S.E., Phillips R.S. Systematic review and meta-analysis investigating the efficacy and safety of probiotics in people with cancer. Support Care Cancer. 2018;26(8):2503-2509. DOI: 10.1007/s00520-018-4216-z
  • 124. Chen C., Wen T., Zhao Q. Probiotics used for postoperative infections in patients undergoing colorectal cancer surgery. Biomed Res Int. 2020;2020:5734718. DOI: 10.1155/2020/5734718
  • 125. Ouyang X., Li Q., Shi M., Niu D., Song W., Nian Q., et al. Probiotics for preventing postoperative infection in colorectal cancer patients: a systematic review and metaanalysis. Int J Colorectal Dis. 2019;34(3):459-469. DOI: 10.1007/s00384-018-3214-4
  • 126. Tang G., Zhang L., Huang W., Wei Z. Probiotics or synbiotics for preventing postoperative infection in hepatopancreatobiliary cancer patients: a meta-­analysis of randomized controlled trials. Nutr Cancer. 2022;74(10):3468-3478. DOI: 10.1080/01635581.2022.2089698
  • 127. Shu Z., Li P., Yu B., Huang S., Chen Y. The effectiveness of probiotics in prevention and treatment of cancer therapy-induced oral mucositis: a systematic review and meta-analysis. Oral Oncol. 2020;102:104559. DOI: 10.1016/j.oraloncology.2019.104559
  • 128. Qiu G., Yu Y., Wang Y., Wang X. The significance of probiotics in preventing radiotherapy-induced diarrhea in patients with cervical cancer: a systematic review and metaanalysis. Int J Surg. 2019;65:61-69. DOI: 10.1016/j.ijsu.2019.03.015
  • 129. Wang Y.H., Yao N., Wei K.K., Jiang L, Hanif S., Wang Z.X., et al. The efficacy and safety of probiotics for prevention of chemoradiotherapy-induced diarrhea in people with abdominal and pelvic cancer: a systematic review and meta-analysis. Eur J Clin Nutr. 2016;70(11):1246-1253. DOI: 10.1038/ejcn.2016.102
  • 130. Devaraj N.K., Suppiah S., Veettil S.K., Ching S.M., Lee K.W., Menon R.K., et al. The Effects of probiotic supplementation on the incidence of diarrhea in cancer patients receiving radiation therapy: a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials. Nutrients. 2019;11(12):2886. DOI: 10.3390/nu11122886
  • 131. Redman M.G., Ward E.J., Phillips R.S. The efficacy and safety of probiotics in people with cancer: a systematic review. Ann Oncol. 2014;25(10):1919-1929. DOI: 10.1093/annonc/mdu106
  • 132. Van den Nieuwboer M., Brummer R.J., Guarner F., Morelli L., Cabana M., Claasen E. The administration of probiotics and synbiotics in immune compromised adults: is it safe? Benef Microbes. 2015;6(1):3-17. DOI: 10.3920/BM2014.0079
  • 133. Ciernikova S., Kasperova B., Drgona L., Smolkova B., Stevurkova V., Mego M. Targeting the gut microbiome: an emerging trend in hematopoietic stem cell transplantation. Blood Rev. 2021;48:100790. DOI: 10.1016/j.blre.2020.100790
  • 134. Cohen S.A., Woodfield M.C., Boyle N., Stednick Z., Boeckh M., Pergam S.A. Incidence and outcomes of bloodstream infections among hematopoietic cell transplant recipients from species commonly reported to be in over-the-counter probiotic formulations. Transpl Infect Dis. 2016;18(5):699-705. DOI: 10.1111/tid.12587
  • 135. Ladas E.J., Bhatia M., Chen L., Sandler E., Petrovic A., Berman D.M., et al. The safety and feasibility of probiotics in children and adolescents undergoing hematopoietic cell transplantation. Bone Marrow Transplant. 2016;51(2):262266. DOI: 10.1038/bmt.2015.275
  • 136. Sadanand A., Newland J.G., Bednarski J.J. Safety of probiotics among high-risk pediatric hematopoietic stem cell transplant recipients. Infect Dis Ther. 2019;8(2):301306. DOI: 10.1007/s40121-019-0244-3
Views
0 Abstract
0 PDF
0 Crossref citations
Shared